| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2011PLoSO...618255Z |
| P356 | DOI | 10.1371/JOURNAL.PONE.0018255 |
| P8608 | Fatcat ID | release_naa3irvi7be3jpxwdz5d434z7q |
| P932 | PMC publication ID | 3071699 |
| P698 | PubMed publication ID | 21483670 |
| P5875 | ResearchGate publication ID | 51042435 |
| P50 | author | Dimitrios Spandidos | Q18701325 |
| George I. Lambrou | Q37376221 | ||
| Apostolos Zaravinos | Q56419727 | ||
| P2093 | author name string | Dimitrios Volanis | |
| Dimitris Delakas | |||
| P2860 | cites work | Identification of common differentially expressed genes in urinary bladder cancer | Q21135503 |
| Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex | Q24295120 | ||
| Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes | Q24534395 | ||
| Statistical significance for genomewide studies | Q24681264 | ||
| Multifactorial experimental design and the transitivity of ratios with spotted DNA microarrays | Q24805395 | ||
| The crystal structure of PEBP-2, a homologue of the PEBP/RKIP family | Q27639063 | ||
| A transforming mutation in the pleckstrin homology domain of AKT1 in cancer | Q27646556 | ||
| Mutations of the BRAF gene in human cancer | Q27860760 | ||
| Angiogenesis in cancer and other diseases | Q27861015 | ||
| RKIP downregulates B-Raf kinase activity in melanoma cancer cells | Q28241040 | ||
| Raf-1 kinase inhibitor protein: structure, function, regulation of cell signaling, and pivotal role in apoptosis | Q28278590 | ||
| A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene | Q28279136 | ||
| Metalloproteinases and their inhibitors in matrix remodeling | Q28305537 | ||
| PI3K/PTEN signaling in angiogenesis and tumorigenesis | Q28383083 | ||
| Angiogenesis in cancer, vascular, rheumatoid and other disease | Q29547165 | ||
| Genesis: cluster analysis of microarray data | Q29619630 | ||
| What Is the Evidence That Tumors Are Angiogenesis Dependent? | Q29620029 | ||
| Immunohistochemical staining for transforming growth factor beta 1 associates with disease progression in human breast cancer | Q31019483 | ||
| PPARgamma-independent induction of growth arrest and apoptosis in prostate and bladder carcinoma | Q33235601 | ||
| Combined determination of plasma MMP2, MMP9, and TIMP1 improves the non-invasive detection of transitional cell carcinoma of the bladder | Q33253538 | ||
| D-type cyclins in superficial and muscle-invasive bladder urothelial carcinoma: correlation with clinicopathological data and prognostic significance | Q33533392 | ||
| Centrosome clustering and cyclin D1 gene amplification in double minutes are common events in chromosomal unstable bladder tumors | Q33601875 | ||
| Dysregulation of apoptosis in cancer | Q33773397 | ||
| Fundamentals of experimental design for cDNA microarrays | Q34161168 | ||
| EGFR and cancer prognosis | Q34399312 | ||
| Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma | Q34570747 | ||
| Estimates of the cancer incidence and mortality in Europe in 2006. | Q34575047 | ||
| Unraveling the complexities of the Raf/MAP kinase pathway for pharmacological intervention | Q34583868 | ||
| Transforming growth factor β1 as a biomarker for prostate cancer | Q35190856 | ||
| Raf kinase inhibitor protein: a prostate cancer metastasis suppressor gene | Q35777189 | ||
| Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia | Q35798342 | ||
| Non-invasive urothelial neoplasms: according to the most recent WHO classification | Q35832133 | ||
| Mechanisms of Disease: genetic and epigenetic alterations that drive bladder cancer | Q36395100 | ||
| Molecular biology of bladder cancer: prognostic and clinical implications. | Q36543207 | ||
| Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation | Q36618743 | ||
| Long-term outcome related to epidermal growth factor receptor status in bladder cancer | Q72539394 | ||
| [Vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) expression in superficial transitional cell bladder carcinoma] | Q73166363 | ||
| Significance of urinary epidermal growth factor and its receptor expression in human bladder cancer | Q73311092 | ||
| Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence | Q73347571 | ||
| The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy | Q73393234 | ||
| In situ hybridization studies of metalloproteinases 2 and 9 and TIMP-1 and TIMP-2 expression in human prostate cancer | Q73394995 | ||
| Screening of H-ras gene point mutations in 50 cases of bladder carcinoma | Q73406379 | ||
| Effects of raf kinase inhibitor protein expression on suppression of prostate cancer metastasis | Q73543723 | ||
| Enhanced urinary gelatinase activities (matrix metalloproteinases 2 and 9) are associated with early-stage bladder carcinoma: a comparison with clinically used tumor markers | Q73937556 | ||
| Molecular mediators of angiogenesis in bladder cancer | Q74356111 | ||
| Role of matrix metalloproteinase-9 in the basement membrane destruction of superficial urothelial carcinomas | Q74614385 | ||
| Numeric aberration of chromosome 17 is strongly correlated with p53 overexpression, tumor proliferation and histopathology in human bladder cancer | Q77125013 | ||
| MMP-9 activity in urine from patients with various tumors, as measured by a novel MMP activity assay using modified urokinase as a substrate | Q78027229 | ||
| [Immunohistochemical expression of p53, p21, p16, and cyclin D1 in superficial bladder cancer. A tissue microarray study] | Q79321298 | ||
| [Role of Ki-67, mutated gene-suppressor p53 and HER-2neu oncoprotein in the prognosis for the clinical course of bladder cancer] | Q79876304 | ||
| Extending the loop design for two-channel microarray experiments | Q79983438 | ||
| Serum tissue inhibitor of metalloproteinase-2 (TIMP-2) and matrix metalloproteinase-2 in complex with the inhibitor (MMP-2:TIMP-2) as prognostic markers in bladder cancer | Q79995929 | ||
| Highly conserved sequence of exon 15 BRAF gene and KRAS codon 12 mutation among Greek patients with colorectal cancer | Q80059973 | ||
| Noninvasive diagnosis of bladder cancer by detection of matrix metalloproteinases (MMP-2 and MMP-9) and their inhibitor (TIMP-2) in urine | Q80232980 | ||
| Expression analysis of VEGFA, FGF2, TGFbeta1, EGF and IGF1 in human nasal polyposis | Q80509721 | ||
| Combination treatment with ionising radiation and gefitinib ('Iressa', ZD1839), an epidermal growth factor receptor (EGFR) inhibitor, significantly inhibits bladder cancer cell growth in vitro and in vivo | Q80564535 | ||
| Mutations and differential expression of the ras family genes in human nasal polyposis | Q81388189 | ||
| Expression of VEGF in urinary bladder transitional cell carcinoma in an Iraqi population subjected to depleted uranium: an immunohistochemical study | Q83200461 | ||
| Multicenter validation of a 1,550-gene expression profile for identification of tumor tissue of origin | Q83583616 | ||
| Expression of basic fibroblast growth factor correlates with resistance to paclitaxel in human patient tumors | Q83897859 | ||
| p16(INK4a) expression analysis as an ancillary tool for cytologic diagnosis of urothelial carcinoma | Q84761597 | ||
| Matrix metalloproteinases and their inhibitors in connective tissue remodeling | Q37174661 | ||
| Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy | Q37540810 | ||
| Transforming growth factor-beta: multifunctional regulator of differentiation and development | Q37583397 | ||
| Metastasis suppressor gene Raf kinase inhibitor protein (RKIP) is a novel prognostic marker in prostate cancer | Q38320789 | ||
| Preferential and novel activation of H-ras in human bladder carcinomas | Q38348091 | ||
| Regulation of Ras signaling specificity by protein kinase C. | Q39458831 | ||
| AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K. | Q39791614 | ||
| Expression of angiogenesis-related genes regulates different steps in the process of tumor growth and metastasis in human urothelial cell carcinoma of the urinary bladder | Q39903524 | ||
| Molecular profiling of bladder cancer: involvement of the TGF-beta pathway in bladder cancer progression. | Q39982746 | ||
| PKBalpha/Akt1 acts downstream of DNA-PK in the DNA double-strand break response and promotes survival | Q39987929 | ||
| Targeting EGFR in bladder cancer | Q40095585 | ||
| Micro-array analysis of the effect of post-transurethral bladder tumor resection urine on transforming growth factor-beta1 dependent gene expression in transitional cell carcinoma | Q40348865 | ||
| Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer | Q40532768 | ||
| Matrix metalloproteinases (MMPs) in bladder cancer: the induction of MMP9 by epidermal growth factor and its detection in urine | Q40667065 | ||
| Excretion of matrix metalloproteinases 2 and 9 in urine is associated with a high stage and grade of bladder carcinoma | Q40713063 | ||
| Signal transduction pathways involving the Raf proto-oncogene | Q40733258 | ||
| Identification of the osteopontin gene as a direct target of TP53. | Q40755207 | ||
| Expression and functions of EGF, FGF and TGFbeta-growth-factor family members and their receptors in invasive human transitional-cell-carcinoma cells | Q41116414 | ||
| Matrix metalloproteinase degradation of elastin, type IV collagen and proteoglycan. A quantitative comparison of the activities of 95 kDa and 72 kDa gelatinases, stromelysins-1 and -2 and punctuated metalloproteinase (PUMP). | Q41678253 | ||
| The role of osteopontin in tumorigenesis and metastasis. | Q41678469 | ||
| Expression of transforming growth factors beta-1, beta 2 and beta 3 in human bladder carcinomas | Q41911470 | ||
| The prevalence of bcl-2, p53, and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates | Q42451765 | ||
| Viral DNA detection and RAS mutations in actinic keratosis and nonmelanoma skin cancers | Q42461687 | ||
| Expression of transforming growth factor beta1 and its receptors in normal human urothelium and human transitional cell carcinomas | Q42470740 | ||
| Mathematical formulae for the prediction of the residual beta cell function during the first two years of disease in children and adolescents with insulin-dependent diabetes mellitus | Q42521348 | ||
| Ha-ras oncogenes are activated by somatic alterations in human urinary tract tumours | Q42818690 | ||
| Expression of basic fibroblast growth factor, its receptors and syndecans in bladder cancer. | Q43263196 | ||
| BRAF and RKIP are significantly decreased in cutaneous squamous cell carcinoma. | Q43524289 | ||
| DNA microarray expression profiling of bladder cancer allows identification of noninvasive diagnostic markers | Q43875320 | ||
| Implication of RAF and RKIP genes in urinary bladder cancer | Q43890261 | ||
| Urinary basic fibroblast growth factor in bladder cancer patients. Histopathological correlation and clinical potential | Q45032715 | ||
| The role of TGF-beta-1 protein and TGF-beta-R-1 receptor in immune escape mechanism in bladder cancer | Q46816755 | ||
| Altered mRNA expression of the Rb and p16 tumor suppressor genes and of CDK4 in transitional cell carcinomas of the urinary bladder associated with tumor progression. | Q47435187 | ||
| Mutational analysis of the BRAF gene in transitional cell carcinoma of the bladder | Q47911813 | ||
| Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies | Q48089758 | ||
| Immunohistochemical positive stained p53 protein in bladder transitional cell carcinoma. | Q51743957 | ||
| Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. | Q51953901 | ||
| Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. | Q52089307 | ||
| Identifying distinct classes of bladder carcinoma using microarrays. | Q52111529 | ||
| Osteopontin overexpression predicts poor prognosis of upper urinary tract urothelial carcinoma. | Q53303542 | ||
| p16ink4 immunoreactivity is a reliable marker for urothelial carcinoma in situ. | Q53324615 | ||
| Mutation Affecting the 12th Amino Acid of the c-Ha- ras Oncogene Product Occurs Infrequently in Human Cancer | Q53559076 | ||
| Matrix metalloproteinase expression in the recurrence of superficial low grade bladder transitional cell carcinoma. | Q53571539 | ||
| p16(INK4a) expression in urinary bladder carcinoma. | Q53585572 | ||
| The epidermal growth factor receptor and the prognosis of bladder cancer. | Q53797133 | ||
| Activation of RAS family genes in urothelial carcinoma. | Q54489900 | ||
| RKIP and BRAF aberrations in human nasal polyps and the adjacent turbinate mucosae. | Q54542900 | ||
| Angiogenesis extent and expression of matrix metalloproteinase-2 and -9 agree with progression of ovarian endometriomas | Q57903528 | ||
| Statistical Methods for Identifying Differentially Expressed Genes in DNA Microarrays | Q58618312 | ||
| Association of Angiogenesis Related Markers With Bladder Cancer Outcomes and Other Molecular Markers | Q59649562 | ||
| Expression of transforming growth factor-beta 1 in prostate cancer. | Q64893650 | ||
| Urinary type IV collagenase: elevated levels are associated with bladder transitional cell carcinoma | Q67832773 | ||
| Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours | Q69856767 | ||
| Overexpression of p53 protein and its significance for recurrent progressive bladder tumours | Q71212915 | ||
| C-erbB-2 in bladder cancer: molecular biology, correlation with epidermal growth factor receptors and prognostic value | Q71566796 | ||
| p53 and erbB-2 protein overexpression are associated with early invasion and metastasis in bladder cancer | Q71612104 | ||
| Expression of p53 product in Chinese human bladder carcinoma | Q72089540 | ||
| Basic fibroblast growth factor and transforming growth factor beta-1: synergistic mediators of angiogenesis in vitro | Q72098027 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | e18255 | |
| P577 | publication date | 2011-04-05 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Spotlight on differentially expressed genes in urinary bladder cancer | |
| P478 | volume | 6 |
| Q93016458 | A Specific Blood Signature Reveals Higher Levels of S100A12: A Potential Bladder Cancer Diagnostic Biomarker Along With Urinary Engrailed-2 Protein Detection |
| Q39424176 | An Osteopontin/CD44 Axis in RhoGDI2-Mediated Metastasis Suppression |
| Q33581255 | Diagnostic potential of urinary α1-antitrypsin and apolipoprotein E in the detection of bladder cancer |
| Q39393301 | Fractal dimensions of in vitro tumor cell proliferation. |
| Q42151958 | Gene expression is highly correlated on the chromosome level in urinary bladder cancer. |
| Q37718676 | Gene expression profiling in bladder cancer identifies potential therapeutic targets |
| Q38480261 | Gene set enrichment analysis of the NF-κB/Snail/YY1/RKIP circuitry in multiple myeloma. |
| Q93002445 | Identification of Key Biomarkers in Bladder Cancer: Evidence from a Bioinformatics Analysis |
| Q36635881 | Interleukin-20 promotes migration of bladder cancer cells through extracellular signal-regulated kinase (ERK)-mediated MMP-9 protein expression leading to nuclear factor (NF-κB) activation by inducing the up-regulation of p21(WAF1) protein expressio |
| Q48593750 | LKB1 mutations and their correlation with LKB1 and Rheb expression in bladder cancer |
| Q31005911 | Multiple criteria optimization joint analyses of microarray experiments in lung cancer: from existing microarray data to new knowledge. |
| Q92485512 | Nimbolide Represses the Proliferation, Migration, and Invasion of Bladder Carcinoma Cells via Chk2-Mediated G2/M Phase Cell Cycle Arrest, Altered Signaling Pathways, and Reduced Transcription Factors-Associated MMP-9 Expression |
| Q89846200 | Osteopontin accelerates the development and metastasis of bladder cancer via activating JAK1/STAT1 pathway |
| Q92891497 | Primmorph extracts and mesohyls of marine sponges inhibit proliferation and migration of hepatocellular carcinoma cells in vitro |
| Q36642294 | Role of the angiogenic components, VEGFA, FGF2, OPN and RHOC, in urothelial cell carcinoma of the urinary bladder |
| Q35119047 | Transcriptome profiling of a multiple recurrent muscle-invasive urothelial carcinoma of the bladder by deep sequencing |
Search more.